AP2006003553A0 - N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors. - Google Patents

N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.

Info

Publication number
AP2006003553A0
AP2006003553A0 AP2006003553A AP2006003553A AP2006003553A0 AP 2006003553 A0 AP2006003553 A0 AP 2006003553A0 AP 2006003553 A AP2006003553 A AP 2006003553A AP 2006003553 A AP2006003553 A AP 2006003553A AP 2006003553 A0 AP2006003553 A0 AP 2006003553A0
Authority
AP
ARIPO
Prior art keywords
amidyl
benzimidazolyl
substituted pyrazolyl
kit inhibitors
inhibitors
Prior art date
Application number
AP2006003553A
Other languages
English (en)
Inventor
Joshua Bolger
Andrew Phillip Crew
An-Hu Li
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AP2006003553A0 publication Critical patent/AP2006003553A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2006003553A 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors. AP2006003553A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49676603P 2003-08-21 2003-08-21
PCT/US2004/026481 WO2005021537A1 (en) 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors

Publications (1)

Publication Number Publication Date
AP2006003553A0 true AP2006003553A0 (en) 2006-04-30

Family

ID=34272512

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003553A AP2006003553A0 (en) 2003-08-21 2004-08-16 N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.

Country Status (19)

Country Link
EP (1) EP1664032B1 (cg-RX-API-DMAC7.html)
JP (1) JP4795237B2 (cg-RX-API-DMAC7.html)
KR (1) KR20060115346A (cg-RX-API-DMAC7.html)
CN (1) CN1839130A (cg-RX-API-DMAC7.html)
AP (1) AP2006003553A0 (cg-RX-API-DMAC7.html)
AR (1) AR045389A1 (cg-RX-API-DMAC7.html)
AT (1) ATE413395T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004268948A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413785A (cg-RX-API-DMAC7.html)
CA (1) CA2536151A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004017623D1 (cg-RX-API-DMAC7.html)
IL (1) IL173616A0 (cg-RX-API-DMAC7.html)
IS (1) IS8320A (cg-RX-API-DMAC7.html)
MX (1) MXPA06002017A (cg-RX-API-DMAC7.html)
NO (1) NO20060665L (cg-RX-API-DMAC7.html)
RU (1) RU2006108791A (cg-RX-API-DMAC7.html)
TW (1) TW200524911A (cg-RX-API-DMAC7.html)
UA (1) UA84712C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005021537A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20090053236A1 (en) 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
JP5583346B2 (ja) * 2006-01-18 2014-09-03 エルジー ハウスホールド アンド ヘルスケア リミテッド ｃ−Ｋｉｔ活性阻害剤、及び、肌美白剤
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
JPWO2014098176A1 (ja) 2012-12-21 2017-01-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
JP6423372B2 (ja) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
SMT202200367T1 (it) 2014-08-28 2022-11-18 Eisai R&D Man Co Ltd Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
JP2829788B2 (ja) 1994-02-10 1998-12-02 ファイザー インク． ベンゾジアゼピン受容体部位アゴニスト及びアンタゴニストとしての５−ヘテロアリールインドール誘導体
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0846689B1 (en) 1996-12-09 2004-01-14 Pfizer Inc. Benzimidazole compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
EP0995742A4 (en) 1997-06-27 2004-08-25 Fujisawa Pharmaceutical Co SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
BR9912571A (pt) 1998-07-28 2001-11-20 Nihon Nohyaku Co Ltd Derivado de diamida de ácido dicarboxìlicoheterocìclico fundido, herbicida, e, processo paraa utilização de um herbicida
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) * 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
CA2369553A1 (en) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl and n-indolylmethyl-benzamides and their use as crf modulators
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085372B1 (en) 1999-09-13 2004-12-22 Eastman Kodak Company Photographic material having improved color reproduction
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
AU2001234705A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
CN1575177A (zh) 2000-12-11 2005-02-02 图拉里克公司 Cxcr3拮抗剂
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
CA2440037C (en) 2001-03-05 2010-02-16 Transtech Pharma, Inc. Benzimidazole derivatives for modulating the rage receptor
JP2004528304A (ja) * 2001-03-12 2004-09-16 アバニール・ファーマシューティカルズ ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process

Also Published As

Publication number Publication date
CA2536151A1 (en) 2005-03-10
AU2004268948A1 (en) 2005-03-10
IL173616A0 (en) 2006-07-05
AR045389A1 (es) 2005-10-26
WO2005021537A1 (en) 2005-03-10
IS8320A (is) 2006-02-21
RU2006108791A (ru) 2006-07-27
BRPI0413785A (pt) 2006-11-07
ATE413395T1 (de) 2008-11-15
JP2007502820A (ja) 2007-02-15
CN1839130A (zh) 2006-09-27
UA84712C2 (en) 2008-11-25
TW200524911A (en) 2005-08-01
DE602004017623D1 (de) 2008-12-18
EP1664032B1 (en) 2008-11-05
MXPA06002017A (es) 2006-05-31
NO20060665L (no) 2006-05-16
KR20060115346A (ko) 2006-11-08
EP1664032A1 (en) 2006-06-07
JP4795237B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
AP2006003553A0 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
AP2006003549A0 (en) N-substituted benzimidazolyl C-kit inhibitors.
EG24774A (en) Quinoline derivatives as phosphodiesterase inhibitors.
SG131944A1 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
EG25482A (en) Inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
TWI369354B (en) Cytokine inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
IL174010A0 (en) Cytokine inhibitors
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
EP1532133A4 (en) NF-: B INHIBITORS
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ZA200707086B (en) Cytokine inhibitors
AP2005003451A0 (en) HIV integrase inhibitors.
EP1704142A4 (en) PROTEASE INHIBITORS
EP1663279A4 (en) MODIFIED PROTEASE INHIBITORS
AU2003230392A8 (en) Beta-secretase inhibitors
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
EP1622615A4 (en) INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0312619D0 (en) Complement inhibitors
HK1091765A (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
GB0329869D0 (en) Inhibitors